

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Amphetamine (Dyanavel XR)

Notes:

- ^ Adequate trial of a long-acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.
- **Adequate trial of a short acting agent is further defined as wearing off that is not resolved by increasing the dose and the frequency to a minimum of twice daily OR clinically significant side effects related to the short-acting dosage form that cannot be resolved by adjusting the dose or timing.
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **amphetamine (Dyanavel XR)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
- Patient has failed an adequate trial ^ of a long-acting dextroamphetamine ER (Dexedrine Spansule), unless allergy to an inactive ingredient
- Patient has failed an adequate trial^ of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) or dexamethylphenidate ER (Focalin XR), unless allergy to an inactive ingredient
- Documented intolerance or contraindication to sprinkle formulations and is unable to swallow whole tablets

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary **amphetamine (Dyanavel XR)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
- Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
- Patient has failed an adequate trial ^ of a long-acting dextroamphetamine ER (Dexedrine Spansule), unless allergy to an inactive ingredient
- Patient has failed an adequate trial^ of a methylphenidate ER (Concerta, Metadate CD, Ritalin LA) or dexamethylphenidate ER (Focalin XR), unless allergy to an inactive ingredient

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Amphetamine (Dyanavel XR)

- Documented intolerance or contraindication to sprinkle formulations and is unable to swallow whole tablets

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **amphetamine (Dyanavel XR)** will be covered on the prescription drug benefit when the following criteria are met:

- Patient is over 21 year of age
 - Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD)
 - Patient has failed an adequate trial ^ of a long-acting amphetamine product (Adderall XR, etc), unless allergy to an inactive ingredient
 - Patient has failed an adequate trial ^ of a long-acting dextroamphetamine ER (Dexedrine Spansule), unless allergy to an inactive ingredient
- OR -**
- Diagnosis of Attention Deficit and Hyperactivity Disorder (ADHD) and patient is age 6 to 20 years old and stable on medication